LONDON, June 22, 2021: Morgan Lewis has advised uniQure N.V., a leading gene therapy company, on its agreement to acquire Corlieve Therapeutics, a private French biotech company. Corlieve’s lead program seeks to employ miRNA silencing technology to treat patients with temporal lobe epilepsy.
The cross-border Morgan Lewis team advising uniQure included partners Tim Corbett, Suzanne Filippi, Louis Beardell, Robert Smyth and Olivier Chambord, and associates Allison Soilihi, Xavier Martin and Deping Chai.